domatinostat/sirolimus (HLX-4310) / 4SC, Healx - LARVOL DELTA

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma (clinicaltrials.gov) - P1/2 | N=74 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute

New P1/2 trial • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Healx…announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310, an investigational oral combination of a class I selective HDAC inhibitor and an mTOR inhibitor, in adolescents and adults with relapsed, refractory sarcoma, with a focus on osteosarcoma. (Yahoo Finance)

Trial status • Osteosarcoma

Vuja De Sciences Announces FDA Clearance of Investigational New Drug (IND) Application for VUJ-100 (PRWeb) - "Vuja De Sciences...announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for VUJ-100 for the treatment of relapsed, refractory sarcoma and osteosarcoma on Sep 11, 2024....The Phase 1/2 trial will be conducted by Sunshine/NPCF with the support of Vuja De."

IND • New P1/2 trial • Osteosarcoma